Radiology dominated FDA authorizations of AI- and machine learning-enabled medical devices through 2025, according to a peer-reviewed study published in Cureus.
The study examined 1,430 authorization records in the FDA’s public AI-enabled device list with authorization dates from September 1995 through December 2025. Here are five things to know:
- Radiology accounted for 76.5% of authorizations. Of the 1,430 authorization records analyzed, 1,094 were in radiology.
- Radiology, cardiovascular and neurology collectively represented 90.6% of authorization records.
- Authorizations accelerated sharply. The annual average increased from 1.8 per year from 1995 through 2014 to 264 per year from 2023 through 2025. There were 331 authorizations in 2025.
- A small group of companies accounted for a sizable share. Among 740 companies, 502 (67.8%) had a single authorized device, while 13 companies (1.8%) accounted for 247 devices (17.3%).
- No authorizations were recorded under the psychiatry or behavioral health review panel. The analysis measured authorization records, not clinical adoption, patient benefit or physician replacement, and the FDA’s AI-enabled device list is not comprehensive.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
